| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
| There are 8 registered members and 86 guests viewing the site. | Follow us on Twitter | Rss Top Picks Feed | Rss Daily Feed |
|
| HOLD | 93.880 | Norman Levine | Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here. | 2008-07-21 | |
| DON'T BUY | 75.970 | Brian Acker, CA | The model price is $48.70, a negative 35% differential. Would choose Amgen (AMGN-Q), which he owns. | 2007-06-21 | |
| DON'T BUY | 74.901 | Charles Lannon | One of the largest bio-tech firms in the world. He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6). Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term. | 2007-06-07 | |
| BUY | 86.650 | David Burrows | The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow. | 2005-07-13 | |
| DON'T BUY | 78.600 | Brian Acker, CA | Model price is $25.24. Very expensive. | 2005-05-24 | |
| TOP PICK | 47.250 | John Sinkins, CFA | Growing revenue profits annually 25%. Good products. Good value at this price. | 2001-08-29 |